The European Medicines Agency (EMA)’s guidelines on conflicts of interest disclosure for patient and consumer groups are an essential tool to evaluate real or perceived conflicts of interest with the pharmaceutical industry. Research from Corporate Europe Observatory has however found that the administration of the guidelines has failed to stop missing or misleading statements from several patient groups which have denied being sponsored by industry, while taking pharma cash.
Read the complete article: www.corporateeurope.org/system/files/files/article/Patient+Groups+Need+a+Strong+Dose+of+Transparency.pdf